Refile: US FDA approves Regeneron's drug for generalized myasthenia gravis
REFILE-US FDA approves Regeneron's drug for generalized myasthenia gravis Corrects day in paragraph 1 to Wednesday from Thursday
Nov 18 (Reuters) - The US Food and Drug Administration has approved Regeneron Pharmaceuticals' REGN.O drug to treat adults with generalized myasthenia gravis who test positive for anti-acetylcholine receptor antibodies, the company said on Wednesday.
(Reporting by Siddhi Mahatole in Bengaluru)
Recent news on Regeneron Pharmaceuticals
See all newsCorrected: UPDATE 2-US FDA approves Regeneron's drug for generalized myasthenia gravis (November 18)
Refile: US FDA approves Regeneron's drug for generalized myasthenia gravis
Brief: Livsayis™ (Cemdisiran) Approved By The FDA As First And Only Sirna Therapy In Generalized Myasthenia Gravis And Only Treatment With Four-Times-A-Year Subcutaneous Dosing
US FDA approves Sanofi's genetic disorder drug
Brief: Regeneron Pharmaceuticals Said Single Administration Of CIDEB(siRNA) Led To Reductions In Liver Fat Up To 80% That Were Sustained Through 36 Weeks